ASCLETIS-B (01672) surged over 5% in early trading, rising 5.02% to HK$14.86 with turnover of HK$20.3604 million as of press time.

On the news front, ASCLETIS announced that its small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for weight loss maintenance demonstrated a 75-day apparent half-life in an ultra-long-acting subcutaneous depot formulation among obese subjects in a U.S. Phase Ib clinical study. This data supports ASC30 as maintenance therapy for long-term weight management with quarterly dosing. The ASC30 weight loss maintenance formulation was developed using ASCLETIS's ultra-long-acting drug development platform.

Dongwu Securities noted that the company has numerous catalysts in the second half of the year, with multiple important clinical data readouts approaching. Based on clinical trial progress and company announcements, Q4 2025 is expected to deliver topline data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 is expected to yield ASC30 subcutaneous injection Phase II topline data. Additionally, the company anticipates submitting 2-3 new pipeline INDs to the FDA within the next 6-9 months, including dual-target peptide weight loss pipelines.